Together, these results demonstrated that PEAR1 AA homozygotes had a strong association with short-term favorable functional outcomes in SAO patients treated with aspirin alone, implying for the first time a potential clinical utility of using PEAR1 rs12041331 SNP as a biomarker for targeted therapeutic strategy in patients with a subtype of acute ischemic stroke. The gene discussed is PEAR1; the disease is southeast Asian ovalocytosis.